Song Xu^1,2,3,4,5,*, Mengxin Lu^1,2,3,4,5, Zhonghua Yang^1,2,3,4,5, Hang Zheng^1,2,3,4,5

Canadian Journal of Urology, Vol.32, No.6, pp. 579-588, 2025, DOI:10.32604/cju.2025.063069 - 30 December 2025

Abstract Background: Many studies have evaluated the performance of fluorescence in situ hybridization (FISH) in detecting urothelial carcinoma, while few of them compared it in detecting bladder cancer (BC) vs. upper tract urothelial carcinoma (UTUC). This study aimed to determine and compare the FISH performance in detecting BC and UTUC. Methods: Data of patients with suspected urothelial carcinoma (UC) who accepted FISH from January 2021 to April 2023 were retrieved. The sensitivity and specificity of FISH in detecting BC and UTUC were determined and compared. Results: A total of 145 BC, 62 UTUC, and 170 non-UC patients were… More >

Jingcheng Lyu^1,2,#, Ruiyu Yue^1,2,#, Yichen Zhu^1,2, Ye Tian^1,2,*, Xinyi Hu^1,2,*

Canadian Journal of Urology, Vol.32, No.5, pp. 411-422, 2025, DOI:10.32604/cju.2025.066758 - 30 October 2025

Abstract Objective: Urothelial carcinoma (UC) remains a prevalent malignancy with high recurrence and chemoresistance rates despite gemcitabine-cisplatin (GC) chemotherapy. The study aimed to identify clinical risk factors for chemoresistance in advanced UC patients and develop a predictive model. Method: A retrospective analysis was conducted on 375 UC patients who received postoperative GC chemotherapy between 2013 and 2024. Patients were categorized into chemotherapy-resistant (CR, n = 91) and non-chemotherapy resistant (NCR, n = 284) groups based on tumor progression. Clinical, pathological, and laboratory variables were compared using t-tests and chi-square tests. Kaplan-Meier assessed overall survival (OS), and binary More >

Marie Chaumel¹, Nicolas Brichart², Franck Bruyère¹, Ali Bourgi^1,*

Canadian Journal of Urology, Vol.32, No.4, pp. 359-366, 2025, DOI:10.32604/cju.2025.066470 - 29 August 2025

Abstract Background: The COVID-19 pandemic disrupted healthcare systems globally, raising concerns about delayed cancer diagnosis and treatment. In France, transurethral resection of bladder tumors (TURBT) was prioritized in national urology guidelines to ensure the timely management of urothelial carcinoma. This study aimed to assess the impact of care reorganization on tumor staging, recurrence, palliative care, and mortality in bladder cancer patients from the pre-pandemic through late-pandemic periods. Methods: We conducted a retrospective multicenter study including all patients who underwent TURBT with histologically confirmed urothelial carcinoma between April and December of 2019 (pre-pandemic), 2020 (early pandemic), 2021… More >

MICHELE MAFFEZZOLI^1,2,#, GIULIA CLAIRE GIUDICE^1,2,#,*, GIACOMO IOVANE^1,2, MARTINA MANINI^1,2, ELENA RAPACCHI¹, GIUSEPPE CARUSO¹, NICOLA SIMONI³, STEFANIA FERRETTI⁴, STEFANO PULIATTI⁴, DAVIDE CAMPOBASSO⁵, SEBASTIANO BUTI^1,2

Oncology Research, Vol.33, No.4, pp. 741-757, 2025, DOI:10.32604/or.2024.057278 - 19 March 2025

Abstract Background: immune checkpoint inhibitors (ICIs) have revolutionized the treatment of metastatic urothelial carcinoma (mUC), significantly improving survival outcomes. However, a subset of patients do not respond to ICIs, prompting research into potential predictive factors. Commonly prescribed medications such as corticosteroids, proton-pump inhibitors (PPIs), antibiotics (Abs), antihypertensives, and analgesics may influence ICI effectiveness. Methods: we conducted a literature search on PubMed to investigate the impact of concomitant medications on the outcomes of patients with mUC, treated with ICIs. We selected the most relevant studies and performed a narrative review. Results: corticosteroids, PPIs and Abs have been associated More >

Oncology Research Editorial Office

Oncology Research, Vol.32, No.11, pp. 1825-1825, 2024, DOI:10.32604/or.2024.056897 - 16 October 2024

Abstract This article has no abstract. More >

Oncology Research Editorial Office

Oncology Research, Vol.32, No.8, pp. 1381-1381, 2024, DOI:10.32604/or.2024.055035 - 17 July 2024

Abstract This article has no abstract. More >

REZA YADOLLAHVANDMIANDOAB^1,#, MEHRSA JALALIZADEH^1,#, FRANCIELE APARECIDA VECHIA DIONATO¹, KEINI BUOSI¹, PATRÍCIA A. F. LEME¹, LUCIANA S. B. DAL COL¹, CRISTIANE F. GIACOMELLI¹, ALEX DIAS ASSIS¹, NASIM BASHIRICHELKASARI¹, LEONARDO OLIVEIRA REIS^1,2,*

Oncology Research, Vol.32, No.4, pp. 597-605, 2024, DOI:10.32604/or.2024.045442 - 20 March 2024

Abstract Bladder cancer (BC) is the 10th most common cancer worldwide, with about 0.5 million reported new cases and about 0.2 million deaths per year. In this scoping review, we summarize the current evidence regarding the clinical implications of single-cell sequencing for bladder cancer based on PRISMA guidelines. We searched PubMed, CENTRAL, Embase, and supplemented with manual searches through the Scopus, and Web of Science for published studies until February 2023. We included original studies that used at least one single-cell technology to study bladder cancer. Forty-one publications were included in the review. Twenty-nine studies showed… More > Graphic Abstract

Aly-Khan A. Lalani

Canadian Journal of Urology, Vol.30, No.4, pp. 11633-11638, 2023

Abstract For more than four decades, platinum-based chemotherapy regimens have served as the established standard-of-care for advanced urothelial carcinoma (aUC). However, advancements in our understanding of cancer biology and tumor microenvironment have reshaped the therapeutic landscape and prognosis of this incurable disease. Immune checkpoint inhibitors (ICIs) that target programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) are firmly established tools in aUC management, leading to enhanced life span and improved quality of life for patients.
In patients who achieved stable disease or better following platinum-based chemotherapy, maintenance therapy with the PD-L1 antibody… More >

Kerith R. Wang¹, Rishabh K. Simhal², Gabriel G. Dinatale³, Li Li³, Thenappan Chandrasekar⁴

Canadian Journal of Urology, Vol.30, No.6, pp. 11752-11755, 2023

Abstract We report a rare case of cystitis cystica and glandularis mimicking low-grade urothelial carcinoma that was found incidentally and treated with resection and fulguration via transurethral resection of bladder tumor (TURBT). When early recurrence was found on surveillance cystoscopy 3 months later, the patient was treated with repeat TURBT and intravesical gemcitabine. Surveillance cystoscopy 4 months later revealed cystitis cystica and cystitis glandularis yet again. We highlight the diagnosis and management of multiple early recurrences of cystitis cystica in this patient, particularly our treatment with gemcitabine and close surveillance. More >

Andrés Ortíz Restrepo¹, Jeffrey S. Ross², Philippe E. Spiess^3,4,5, Andrea Necchi⁶, Roger Li⁴, Herney Andrés García-Perdomo^1,7

Canadian Journal of Urology, Vol.29, No.6, pp. 11378-11383, 2022

Abstract Introduction: Urothelial carcinoma (UC) is the fourth most prevalent malignancy in adults, accounting for 2.1% of cancer-related deaths. We aimed to describe the most frequent telomerase reverse transcriptase (TERT) gene mutations in this type of cancer and their relationship with the prognosis and treatment of this disease.
Materials and methods: We performed a search strategy in Medline and Embase with the following keywords: telomerase reverse transcriptase (TERT) gene and upper tract UC. We included reviews and observational studies to support the statements throughout the manuscript.
Results: The transcriptional activation of the TERT gene and subsequent telomerase activity is… More >